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Abstract
Ménétrier’s disease is a rare, premalignant disorder of the stomach with no proven effective
medical therapy. Increased epidermal growth factor (EGF) receptor signaling has been implicated
in the pathogenesis of Ménétrier’s disease. We conducted a single-arm clinical trial with
cetuximab, a monoclonal antibody that blocks EGF receptor signaling, in 9 individuals with
clinically and histologically documented severe Ménétrier’s disease that impaired quality-of-life to
the extent that gastrectomy was being considered. Of the 7 patients who completed the one-month
course of treatment, all showed statistically significant improvement both clinically (quality-of-life
indices) and biochemically (increased parietal cell mass and gastric acidity). Furthermore, all
seven patients who completed the one-month trial elected to continue treatment, and four
subsequently showed near complete histological remission. Cetuximab should be considered first
line therapy for Ménétrier’s disease.
Introduction
Ménétrier’s disease (hypoproteinemic hypertrophic gastropathy) is a premalignant
hyperproliferative disorder of the stomach that is characterized by diffusely enlarged gastric
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folds, decreased acid production, excess mucus secretion and decreased serum albumin
(hypoalbuminemia) due to loss of protein across the gastric mucosa [1]. It usually involves
the gastric body (corpus) and spares the antrum. The normal mucosa of the gastric body is
made up of relatively short pits and tightly packed specialized glands. The pits are lined by
mucus-secreting surface cells called foveolar epithelium that normally occupy ¼ of the
mucosal thickness. The specialized glands are composed of acid-secreting parietal cells and
mucus-secreting neck cells, which give rise to pepsinogen-secreting zymogenic (chief) cells,
as well as scattered endocrine cells. The normal pit to gland ratio is 1:4 (Fig. 1B, right
panel). In Ménétrier’s disease, this ratio can be reversed (Fig. 1B, left panel) since the
number of surface mucous cells is greatly increased. This histological finding, termed
foveolar hyperplasia, is characteristic of, but not pathognomonic for, Ménétrier’s disease.
The hyperplasia is driven by expansion of the progenitor cells that are normally confined to
the region between the pit and gland designated the isthmus (Fig. 1B, right panel). In
Ménétrier’s disease, these progenitor cells are thought to preferentially differentiate into
surface mucous cells at the expense of parietal cells and chief cells.
The diagnosis of Ménétrier’s disease is based on clinical, endoscopic and histological
criteria. To establish the diagnosis, patients must exhibit relevant signs and symptoms that
usually include hypoalbuminemia and edema, diffusely enlarged folds in the body of the
stomach, prominent foveolar hyperplasia and glandular atrophy with reduced numbers of
parietal cells and chief cells. In adults, it is a progressive disorder; there are no reports of
spontaneous regression of the disease in patients with symptoms longer than 6 months
duration [2–7]. Patients exhibit a constellation of symptoms, which can include abdominal
pain, nausea and vomiting, peripheral edema and chronic gastric blood loss [8]. There has
been no effective medical therapy, and many patients require gastrectomy as a result of
intractable symptoms and concern about gastric cancer.
Evidence from both mice and humans has implicated increased signaling through the EGF
receptor in the pathogenesis of Ménétrier’s disease [9, 10]. Transforming growth factor-α
(TGFα), one of seven mammalian EGF receptor ligands, increases gastric epithelial cell
proliferation, stimulates gastric mucin production and suppresses gastric acidity [11–14].
Transgenic mice that overexpress TGFα in the stomach exhibit all of the histological
features of the disorder [9, 11–13]. Patients with Ménétrier’s disease exhibit increased
TGFα immunoreactivity in the areas of abnormal gastric mucosa [14].
On the basis of this evidence and the lack of any effective medical therapy, the U.S. Food
and Drug Administration (FDA) gave compassionate-use approval to treat a patient with
cetuximab, a recombinant, chimeric, IgG1 monoclonal antibody that binds specifically to the
extracellular portion of the EGF receptor and inhibits binding of ligands such as TGFα.
Treatment of this individual resulted in marked clinical and biochemical improvement [15].
This outcome led us to conduct a single-arm clinical trial to evaluate the effectiveness of
cetuximab in the treatment of Ménétrier’s disease. All seven patients who completed the
one-month course of cetuximab showed improvement in both quality-of-life and
biochemical indices of the disease and elected to continue treatment. Four of the seven
patients had near complete histological resolution of the findings of Ménétrier’s disease.
Results
Patient characteristics
Baseline characteristics of patients enrolled in the trial are presented in Table 1. Of the nine
patients enrolled, five were men and four were women. The ages of the patients at the time
of initial presentation with Ménétrier’s disease ranged from 29 to 79. Of note, four patients
(44.4%) also had ulcerative colitis. Of the 4 patients with ulcerative colitis, two (patients 3
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and 7) had been treated previously with both immunomodulator therapy (6-mercaptopurine)
and a chimeric monoclonal antibody to TNF-α (infliximab). Patient 8 received 6-MP alone
and patient 5 received no immunomodulator therapy. Only one patient was maintained on
immunomodulator therapy while enrolled in the trial (patient 3). Table 1 also presents the
predominant complaint(s) of each patient.
Each participant was treated with a loading dose of intravenous cetuximab (400 mg per
square meter of body surface area), followed by three weekly intravenous infusions (250 mg
per square meter of body surface area). One patient (patient 8) withdrew from the study after
a single dose of cetuximab because of concern over possible side effects from the
medication, although there was no overt toxicity at the time of withdrawal. There was,
however, a marked reduction in Ki-67 immunostaining, a marker of actively cycling cells, in
the involved gastric mucosa 24 hours after the initial dose of cetuximab (Fig. S1). Another
patient (patient 9) received two infusions of cetuximab prior to withdrawal. In this case, his
major symptom, abdominal pain, persisted. When the baseline gastric biopsies were
reviewed after the second dose of cetuximab, a focus of gastric cancer was observed and the
patient was removed from the study.
Response to cetuximab treatment
All seven patients who completed the course of treatment reported improvement in their
individual predominant symptom(s) within one week of starting treatment, usually within 1
to 2 days. Table 2 presents the primary and secondary outcomes at baseline and after one
month of therapy. There was a statistically significant increase in the primary outcome, both
the overall quality-of-life index (Ferrans and Powers QLI; P=0.02) and the QLI Health and
Functioning subscale (P=0.01). Parietal cell mass, as measured by quantitative
immunohistochemistry of the parietal cell marker H+/K+-ATPase (see Materials and
Methods), increased three-fold after one month of therapy (P=0.01) and was accompanied
by a decrease in mean gastric pH from 6.0 to 4.0 (P=0.05). Mean stomach wall thickness
decreased from 13.7 to 9.6 mm, although this was not statistically significantly different
(P=0.06). No significant change was detected in other secondary outcomes. Shown as an
example in Figure 1, patient 4 exhibited a large reduction in gastric wall thickness (as
assessed by CT scan), regression of foveolar hyperplasia and reappearance of parietal cells
with restoration of gastric acidity after four weekly doses of cetuximab.
Although the primary end point (overall QLI) was evaluated after four weekly infusions of
cetuximab, we performed gastroscopy 24 hours after the first infusion and obtained grossly
involved gastric tissue for analysis. After this short time interval, the parietal cell mass had
increased from 20.9 to 41.1 (P=0.02). Figure 2 shows H+/K+-ATPase immunostaining (a
selective marker of parietal cells) at baseline, after one day and after one month of
cetuximab in patients 1 and 3. To confirm this finding, we pooled pre-treatment samples and
one day post-treatment samples from abnormal gastric tissue from 8 patients and performed
in-depth shotgun proteomics. This analysis identified a total of 1090 high-confidence protein
groups; using conservative filtering and grouping algorithms on the original 3806 protein
identifications (See Materials and Methods for details). A total of 47 proteins were
statistically significantly different between pre- and post-treatment by at least 2-fold (32
increased and 15 decreased) (Table S1). In shotgun proteomic datasets, proteins are
identified by mass spectrometry spectra where higher numbers of observed spectra are
interpreted as a measure of protein abundance in the specimen. There was a statistically
significant three-fold increase in normalized spectral counts for the α-subunit of H+/K+-
ATPase after one day of cetuximab treatment (from 7 to 36 spectral counts, quasi-P=0.049);
the β-subunit showed a smaller increase after treatment that did not reach statistical
significance (from 15 to 24 spectral counts, quasi-P=0.98). We also identified significant
increases in proteins previously identified as markers of parietal cells, mucous neck cells
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and chief cells. For example, carbonic anhydrase II and calmodulin 2 are expressed by
parietal cells [16, 17], mucin 6 is expressed by mucous neck cells [18] and gastric lipase and
leucine aminopeptidase 3 are preferentially expressed in chief cells [19, 20] (Table S1).
In addition, we assessed two markers of cellular proliferation, Ki-67 and phosphorylated
MAPK, after the first dose of cetuximab in all seven patients who completed the trial. The
number of Ki-67-positive cells per gland decreased from 43.8 before treatment to 27.2 after
24 hours (P=0.05). Results from patient 7 are shown in Fig. 2B. The ratio of phosphorylated
(activated) MAPK to total MAPK by western blotting decreased from 1.35 (± 2.62) before
treatment to 0.56 (± 1.78) after 24 hours, although this did not reach statistical significance
(P=0.12). Taken together, these results show that monoclonal antibody blockade of the EGF
receptor in this hyperproliferative disorder of the stomach caused a rapid response. In
addition, these findings support the hypothesis that enhanced EGF receptor signaling directs
gastric progenitor cells down a surface mucous cell lineage rather than a parietal cell lineage
[21], and underscore the remarkable plasticity of the adult stomach.
Long term follow-up
All seven participants who completed the trial reported that their predominant symptom(s)
had improved to the extent that they elected to continue treatment (mean duration of
followup 18 months; range 8 to 40 months). Table 3 presents the long-term clinical
outcomes for each patient, along with the histological findings and gastric pH at last follow-
up or at the time of gastrectomy.
After 18 months of cetuximab, patient 1 had complete resolution of symptoms and a
histologically normal stomach (Fig. 3), leading to discontinuation of cetuximab. Nine
months later, the stomach was grossly normal with minimal foveolar hyperplasia and a
gastric pH of 1. She remains asymptomatic 19 months after discontinuing cetuximab. Patient
2 was treated for 16 months, at which time her gastric mucosa appeared grossly and
histologically normal with a gastric pH of 2 (Fig. 3). Cetuximab was stopped and she notes
only occasional nausea 4 months later. Patient 3 has been treated with cetuximab for 40
months. Gastric histology at 31 months showed mild to moderate foveolar hyperplasia (Fig.
S2); however, 7 months later, gastric histology showed marked improvement with reduced
mucosal thickness, minimal foveolar hyperplasia with a gastric pH of 3. He presently
experiences occasional nausea and vomiting and has minimal edema.
Four of the 7 patients who completed the one-month trial eventually underwent gastrectomy.
Patient 4 had complete regression of foveolar hyperplasia after one month of treatment (Fig.
1). He continued on cetuximab for nine months because of continuing abdominal pain. After
9 months of treatment, he underwent gastrectomy due to anxiety about the development of
gastric cancer and concern regarding the need for indefinite cetuximab treatment. His
stomach was normal histologically at the time of surgery (Fig. S3). Patient 5 underwent
gastrectomy when a 4-cm dysplastic lesion was found in the stomach during surveillance
gastroscopy more than a year after she electively discontinued treatment. Patient 6 had
cessation of gastric bleeding while on cetuximab but elected to undergo gastrectomy
because he did not want to continue cetuximab indefinitely. Patient 7 experienced an
infusion reaction after 8 months of treatment and elected to undergo gastrectomy. However,
each of the patients that ultimately underwent gastrectomy had significant improvement in
their predominant symptom(s) during the course of the one-month trial and had elected to
continue treatment.
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Adverse events in response to cetuximab treatment
There has been no evidence of resistance or diminishing benefit over time in response to
long-term treatment with cetuximab. There were no anaphylactic infusion reactions.
However, one patient (patient 7) did have an infusion reaction after approximately 8 months
of therapy that led him to discontinue therapy. Six of the seven patients who received more
than a single infusion developed a rash characteristic of cetuximab therapy [22]. One patient
(patient 5) never developed a rash despite an objective response to treatment, a finding at
odds with the impression that the severity of the rash correlates with the likelihood of a
clinical response to cetuximab in cancer patients [21].
Discussion
This single-arm clinical trial demonstrates efficacy of cetuximab in the treatment of
Ménétrier’s disease, a disorder that has been considered refractory to medical therapy. All of
the patients had severe disease and would have undergone gastrectomy had they not enrolled
in this clinical trial. Despite the small sample size, all seven patients who completed the one-
month trial showed significant improvement in quality-of-life indices as well as significantly
increased parietal cell mass and gastric acidity. As noted above, Ménétrier’s disease is a rare
disorder (www.rarediseases.org); it required 8 years to accrue nine patients, making it
unfeasible to include a placebo control arm.
We were able to perform gastroscopy to obtain gastric tissue 24 hours after the initial
infusion of cetuximab. Even at this early time, there was already a significant decrease in the
number of Ki-67 positive cells in the involved gastric mucosa and a doubling of the parietal
cell mass. The finding of increased parietal cell mass within 24 hours of cetuximab
treatment is consistent with previous investigations in rodents with acute ablation of parietal
cells with DMP-777, a cell-permeant neutrophil elastase inhibitor and parietal cell-specific
protonophore [22]. Following cessation of treatment with DMP-777, parietal cells
expressing H+/K+-ATPase rapidly return within 24 to 48 hours [22]. Additionally, there was
a seven-fold increase in an ultrastructurally defined, immunohistochemically H+/K+-
ATPase-negative, pre-parietal cell population in a transgenic mouse model in which parietal
cells were ablated by H+/K+-ATPase-promoter-driven expression of an attenuated
Diphtheria Toxin A subunit [23, 24]. We have hypothesized that excess EGF receptor
stimulation in Ménétrier’s disease results in overproduction of surface mucous cells at the
expense of glandular lineages [21]; the results in animals cited above suggest the possibility
that in patients with Ménétrier’s disease, there is a relative abundance of H+/K+-ATPase-
negative preparietal cells which are held in a state of suspended maturation, but poised to
differentiate rapidly upon EGF receptor blockade.
All seven participants who completed the trial elected to continue treatment because of
improvements in their predominant symptom(s). There was no evidence that any of these
patients treated with prolonged therapy developed resistance to cetuximab. In fact, the
interval between infusions was increased to every two to three weeks and most showed
continued clinical and histological improvement over time. Patients 1 and 2 were able to
stop treatment altogether after remission of both symptoms and histological features of the
disease. Patient 3 has been on treatment for over 3 years and continues to show progressive
histological improvement after 38 months compared to biopsies after 31 months (Fig. 3 and
Fig. S2). This suggests that prolonged therapy may provide continued benefit for some
patients.
There have been anecdotal case reports of Ménétrier’s disease patients responding to various
pharmacological interventions, including corticosteroids [25]; however, no consistent
benefit has been observed. On the basis of the reported high incidence of infusion reactions
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to cetuximab in patients in the southeastern United States [26], dexamethasone (20 mg
orally) was administered to five of the patients 20 minutes prior to cetuximab infusion.
Although possible, we consider it highly unlikely that this contributed to the beneficial
responses, because the patients that have been treated successfully with corticosteroids such
as dexamethasone for Ménétrier’s disease received much higher, continuous dosing.
Moreover, five of our patients (Patients 1, 3, 5, 7 and 8) had already been treated with
continuous, high-dose corticosteroids for Ménétrier’s disease-associated symptoms without
any appreciable benefit prior to enrolling in this trial.
A notable feature of our study population was that four of nine (44%) participants also had
ulcerative colitis (Table 1). Seven patients with concurrent Ménétrier’s disease and
ulcerative colitis have been reported previously [27, 28]. EGF is involved in healing of the
gastrointestinal mucosa, and EGF enemas are effective at reducing disease activity in
ulcerative colitis [29]. As a result, there was concern that pharmacological blockade of EGF
receptor could exacerbate colitis in these patients. However, none of the four patients with
ulcerative colitis had worsening of their colitis symptoms, even with prolonged treatment,
and periodic colonic biopsies from these patients did not show evidence of increased
histological severity (as an example, sequential images from patient 3 are shown in Fig. S2).
The mechanism underlying the association of Ménétrier’s disease and ulcerative colitis is
not known [30]. All four patients with ulcerative colitis had pancolitis, although the duration
and severity of the disease varied. In all cases, the diagnosis of ulcerative colitis preceded
that of Ménétrier’s disease. There was no common therapeutic regimen; two of the patients
had received infliximab and 6-MP, one patient received 6-MP alone and one patient
received no immunomodulator therapy. Possible underlying factors that may link these two
disorders include upregulation of EGF receptor ligands and a “leaky” mucosa that may
provide a portal of entry for luminal contents (including commensal bacteria or their
products). Whether these or other factors are operative or provide a link between the two
disorders remains to be determined. Patient 2 had ankylosing spondylitis, suggesting a
possible immunological underpinning to Ménétrier’s disease.
From this trial, we cannot draw any firm conclusions regarding the ability of cetuximab to
prevent malignant progression. One of our patients had coexisting gastric cancer that was
only recognized after the second dose of cetuximab. The only patient in our study who
developed a premalignant lesion during prolonged follow-up had stopped cetuximab therapy
approximately 12 months prior to discovery of the lesion.
Although the precise etiology of Ménétrier’s disease remains uncertain, our results suggest
that a common feature of all cases of Ménétrier’s disease is enhanced EGF receptor
signaling. A form of the disorder, which is seen predominantly in children, has been
associated with CMV infection [31–36]. These patients usually have an acute presentation
and spontaneous remission of symptoms and histological findings. When examined,
increased TGFα immunoreactivity has been observed in the involved gastric mucosa of
these cases [37]. Interestingly, the principal envelope glycoprotein of CMV, glycoprotein B,
binds EGF receptor, induces EGF receptor-HER3 heterodimers and activates PI3K-AKT
signaling [38].
This trial suggests that blocking ligand binding to the EGF receptor with cetuximab is an
effective treatment for patients with Ménétrier’s disease. The patients in this study had
severe disease, had failed all medical therapy and were considering gastrectomy as the
remaining treatment option. Prior to treatment, some were considered poor candidates for
surgery due to their hypoalbuminemia and poor nutritional status. The seven patients who
completed the one-month trial experienced rapid clinical and biochemical improvement and
elected to continue treatment. Four of the patients subsequently had near complete
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histological remission, and two have remained asymptomatic off treatment for 19 and 4
months, respectively. Five of the patients ultimately required gastrectomy. In the subset of
patients with Ménétrier’s disease who are too ill to undergo gastrectomy, cetuximab may be
a reasonable bridge to improve their operative risk. Since no other medical therapies have
shown to be consistently beneficial, cetuximab should be considered as first line therapy for
Ménétrier’s disease. It would be of interest to determine whether an oral EGF receptor
tyrosine kinase inhibitor and/or a TACE inhibitor to block cell surface cleavage of TGFα
would be as effective in this disorder as intravenous delivery of the EGF receptor
monoclonal antibody [39].
Materials and Methods
Overview
This single-arm clinical trial explored the safety, tolerability and clinical and biochemical
effect of a four-week course of cetuximab in patients with clinically and histologically
confirmed Ménétrier’s disease. Patients were recruited from seven U.S. states and two
counties. After recruitment, all participants were enrolled and treated during the one-month
trial at the Vanderbilt University Clinical Research Center. This prospective, open-label trial
was approved by the Vanderbilt University Medical Center Institutional Review Board, and
all participants provided written informed consent.
Patients
Individuals aged 18 to 80 years with symptomatic Ménétrier’s disease that interfered with
daily life to the extent that gastrectomy was being considered were eligible for the study.
The diagnosis of Ménétrier’s disease was based on clinical and histological criteria. Prior to
enrollment, all patients underwent upper endoscopy, which revealed enlarged gastric folds,
and histological evaluation that demonstrated foveolar hyperplasia. Two distinct histological
patterns of Ménétrier’s disease have been proposed: massive foveolar hyperplasia (MFH)
with minimal inflammation and hypertrophic lymphocytic gastritis (HLG) [40]. All of the
patients within our study had MFH with little, if any, inflammation. Symptoms in all
patients were refractory to other medical therapy such as proton pump inhibitors,
anticholinergic medications, or anti-emetics for at least six months. There have been case
reports of Ménétrier’s disease linked to H. pylori that were responsive to H. pylori
eradication [41–43]. Therefore, patients with active CMV or H. pylori infection were
excluded from this study. We also required that patients’ symptoms exceed 6 months in
duration prior to entry into the trial to minimize the likelihood of a spontaneous remission.
Patients were also excluded if they were pregnant or breastfeeding, had clinically unstable
cardiovascular disease, had any unstable coagulation disorder, or had any other active
medical condition requiring stabilization, such as malignancy, uncontrolled diabetes,
uncontrolled hypertension or infection requiring antibiotics. Patients receiving concurrent
monoclonal antibody therapy for other medical conditions were ineligible.
Treatment
Participants received intravenous cetuximab once weekly with an initial loading dose of 400
mg per square meter of body surface area, followed by three weekly doses of 250 mg per
square meter of body surface area. To prevent infusion reactions, all patients were
premedicated with diphenhydramine (50 mg intravenously) and 5 of the 9 patients also
received dexamethasone (20 mg orally). If a participant had subjective improvement in
either their predominant symptom(s) or improvement in biochemical or histological
parameters, such as hypoalbuminemia, transfusion requirements, histological changes or
indices of proliferation, then he or she could elect to continue treatment beyond the one-
month trial. For longer term treatment, arrangements were made for patients to receive
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cetuximab at a medical facility near their homes under a separate IRB-approved protocol,
and patients were under the care of their referring physicians. Efforts were made to extend
the interval between treatments from weekly to every two to three weeks without dose
adjustment. Patients received follow-up gastroscopy every 3 to 6 months.
End points
Outcomes were assessed at three time points during the 4-week trial: at baseline, 24 hours
after the loading dose of cetuximab and after the fourth dose. Patients had upper endoscopy
performed at each of these three time points with multiple large forceps pinch biopsies taken
from the body and antrum of the stomach and a full thickness snare biopsy taken from the
body of the stomach. Samples were placed in formalin overnight and then transferred to
70% ethanol for immunohistochemical analysis, or were snap frozen in liquid nitrogen and
stored at −80°C. Gastric fluid samples were tested with pH paper. Serum albumin and
gastrin were measured at each of these time points through the Vanderbilt University
Medical Center diagnostic laboratory. Patients had a CT scan of the abdomen and pelvis
after administration of VoLumen and intravenous contrast at baseline and at the end of the
trial. Stool samples were collected at baseline and at the end of treatment to assess changes
in stool α1-antitrypsin.
The primary outcome was the change from baseline in overall quality-of-life after one
month of treatment, as measured by Ferrans and Powers QLI (Generic Version) and the QLI
Health and Functioning subscale [44]. The Ferrans and Powers QLI measures quality-of-life
across four domains (health and functioning, social and economic, psychological and
spiritual, and family dynamics). This scale was chosen because it has been previously
validated in patients with various chronic medical conditions, including cancer, chronic
kidney disease, and cardiovascular disease, and was also used in our previous report on the
use of cetuximab in Ménétrier’s disease [15]. Secondary outcomes were baseline to one-
month changes in stomach wall thickness, parietal cell mass, gastric pH, Ki-67
immunohistochemistry, total and activated phospho-MAPK levels in the involved gastric
mucosa, serum albumin and gastrin levels and stool α1-antitrypsin. Stomach wall thickness
was measured along the greater curvature of the stomach on CT scan of the abdomen after
administration of intravenous contrast and VoLumen oral contrast. Ki-67 positivity was
expressed as the average number of positive cells per gland based upon counting at least 10
well-oriented glands. All biopsies were reviewed and scored by a single pathologist (MKW).
Stool α1-antitrypsin was measured in a single stool sample from each time point. Total and
phospho-MAPK were assessed by western blot with rabbit polyclonal antibodies p44/42
MAPK (Erk1/2) and phopho-p44/42 MAPK (Erk1/2) (Cell Signaling Technology), with
goat antibody to rabbit horseradish peroxidase (HRP) serving as the secondary antibody.
Western blot results were quantified with densitometry. Because the severity of Ménétrier’s
disease can vary from region to region within the stomach, three separate biopsies from each
patient were pooled from each time point for western blot analysis.
Assessment of parietal cell mass
Parietal cell mass was quantified with an Ariol SL-50 scanner for quantitative
immunohistochemistry with an antibody against the α-subunit of the H+/K+-ATPase (clone
12.18, at 1:2000, a gift from Adam Smolka, Medical University of South Carolina,
Charleston, SC) followed by alkaline phosphatase–conjugated goat antimouse IgG (with
Vector Red substrate detection). Parietal cell mass was calculated based on number and
intensity of H+/K+-ATPase immunoreactivity as described previously [45].
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Shotgun proteomic analysis
The primary tissues were processed by using a previously described protocol [46]. Briefly,
the tissues were solubilized in trifluoroethanol and equal amounts of 100 μg protein from 8
pre- and 8 post-treatment biopsy lysates were pooled for analysis. The homogenates were
processed, digested with trypsin and the resulting peptide mixtures were separated into 20
fractions by isoelectric focusing. Each of these fractions was subjected to analysis by LC-
MS/MS on a Thermo LTQ instrument. Mass spectrometry data was searched using the
MyriMatch version 1.5.2 search algorithm [47] against the human International Protein
Index (IPI) database version 3.37 supplemented with 73 potential contaminant sequences in
forward and reverse orientation. The search results were filtered and assembled with
IDPicker version 2.0 [48]. Peptide identification stringency was set at a maximum of 2.5%
reversed peptide identifications (5% overall peptide false discovery rate, FDR) and a
minimum of two distinct peptides to identify a given protein within the full dataset. Distinct
peptides have dissimilar precursor masses or charge states but may reflect variant peptides
of the same primary protein sequence. Parsimony analysis was applied so that IPI database
entries that mapped to the identical set of peptide identifications were assigned to ”protein
groups” [48]. Such protein groups consist almost exclusively of isoforms or identical
proteins resulting from redundancy in the database. We performed statistical analyses by
modeling spectral count data using a quasi-likelihood Poisson model [49, 50]. Proteins with
at least a two-fold increase in spectral counts and a FDR-corrected quasi P-value of less than
0.05 were considered to be different between the pre- and post-treatment groups. Fold-
changes are calculated from the model-derived rates for each group and are normalized for
the total number of confident spectral identifications observed in each replicate mass
spectrometry analysis.
Statistical analysis
Continuous variables were expressed as means ± SD. Due to the lack of reliability of the
asymptotic paired t-test with such a small sample size, paired differences for all measures
were examined using nonparametric, exact permutation methods. When the null hypothesis
of no change is true, exact tests may be unduly conservative, resulting in P-values larger
than the nominal 5% commonly used as a boundary between non-significance and
significance. Consequently, we report mid-P-values, which use only ½ (versus all) of the
probability of the observed data as part of the extreme values that comprise a P-value [51].
Two patients who withdrew early from the study were not included in the statistical analysis.
StatExact version 8.0 was used for all analyses and SAS version 9.2 was used to estimate
means and standard deviations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
Response to one-month course of cetuximab in patient 4. (A) Patient 4 showed a marked
reduction in stomach wall thickness by CT scan. An equivalent amount of VoLumen (an
oral contrast agent) was administered prior to the scans. Arrows, thickness of gastric wall.
(B) Biopsies before and 1 month after treatment show regression of foveolar hyperplasia and
restoration of glandular mucosa with return to normal pit to gland ratio of 1:4. Surface
mucous cells are strongly positive and mucous neck cells are weakly positive by diastase-
resistant periodic acid-Schiff staining. Gastric pH decreased from 7 to 2 after 4 weekly
infusions of cetuximab. Scale bar is 250 microns.
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Fig. 2.
Recovery of parietal cells and decrease in proliferation one day after initiation of cetuximab
treatment. (A) Patients 1 and 3 demonstrated rapid (one day) and sustained (one month)
increases in H+/K+−ATPase α-subunit immunoreactivity. Scale bar is 250 microns. (B)
Patient 7 had a dramatic decrease in Ki-67 staining one day after first dose of cetuximab.
Scale bar is 250 microns.
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Fig. 3.
Progressive improvement in gastric histology during cetuximab treatment. Foveolar
hyperplasia [with characteristic cysts (arrow in top left panel) and tortuous glands (arrow in
middle left panel)] and glandular atrophy are evident the day before treatment by
hematoxylin-eosin staining. At last follow-up, patients 1, 2 and 3 showed reduced thickness
of gastric mucosa, regression of foveolar hyperplasia and restoration of glandular mucosa
and gastric acidity. Cetuximab has been discontinued in patients 1 and 2. Patient 3 had the
most distorted architecture at presentation. Progressive histological improvement was noted
beginning at 31 months (Fig. S2) and last follow-up at 38 months. Scale bar is 250 microns.
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Table 1
Patient characteristics
Patient Age Sex Ulcerative colitis Predominant symptom(s)
1 79 Female No Abdominal pain, N/V*, edema
2 48 Female No Nausea
3 29 Male Yes Abdominal pain, N/V*, edema
4 41 Male No Abdominal pain, N/V*, edema
5 51 Female Yes Nausea, edema
6 57 Male No Gastric blood loss
7 33 Male Yes Abdominal pain, N/V*
8 57 Female Yes Edema, nausea
9 54 Male No Abdominal pain
*N/V, nausea and vomiting
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Table 2
Effects of one-month treatment with cetuximab on patient parameters. N=7 for each parameter shown; data are
expressed as mean ± SD.
Pre-Treatment 1 Month Difference (Pre - 1 Month) P-valueh
QLIa 15.8 (±6.3) 20.3 (±5.2) −4.4 (±3.4) 0.02
QLI-H&Fb 12.3 (±7.4) 19.8 (±6.2) −7.5 (±4.8) 0.01
Parietal cell massc 20.9 (±17.6) 61.2 (±23.3) −40.2 (±15.8) 0.01
Gastric pH 6.0 (±2.5) 4.1 (±2.7) 2.0 (±2.0) 0.05
Stomach wall thickness (mm)d 13.7 (±6.4) 9.6 (±8.0) 4.1 (±3.4) 0.06
Ki-67 positivitye 43.8 (±25.2) 34.2 (±18.4) 9.6 (±15.6) 0.21
Serum gastrin (pg/mL) 194 (±212) 245 (±240) −51.4 (±160.4) 0.57
Serum albumin (g/dL) 3.04 (±0.55) 3.02 (±0.83) 0.01 (±4.9) 0.97
Stool α1-antitrypsin (g/mg)f 0.92 (±0.73) 0.49 (±0.74) 0.43 (±5.3) 0.19
MAPK Ratiog 1.35 (± 2.62) 0.95 ± (1.88) 0.17 (±0.53) 0.27
a
Ferrans and Power Quality-of-Life Index (QLI). Higher scores indicate a higher QLI. The maximal score possible is 30.
b
Ferrans and Powers QLI, Health and Functioning subscale. The maximal score possible is 30.
c
Proportion of cells expressing H+/K+-ATPase, as measured by quantitative immunohistochemistry [45].
d
Measured along the greater curvature of the stomach on CT scan of the abdomen after administration of intravenous contrast and VoLumen oral
contrast.
e
Mean number of Ki-67 positive cells per gland.
f
Measured in a single stool sample from each patient at each time point.
g
Ratio of intensity of phospho-MAPK divided by total-MAPK determined by densitometry on western blot.
h
mid-P-value (See statistical analysis section of Materials and Methods section)
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Table 3
Long term clinical outcomes for those who continued treatment
Patient Duration of therapy Long-term outcome Gastric histology at last follow-up Gastric pH at last follow-up
1 18 months Off Treatment Minimal FH* 1
2 16 months Off Treatment Minimal FH* 2
3 40 months On Treatment Minimal FH* 3
4 9 months Gastrectomy Normal 2
5 24 months Gastrectomy Dysplastic lesion one year after treatment stopped 7
6 9 months Gastrectomy FH* 2
7 8 months Gastrectomy FH* 3
*
FH, foveolar hyperplasia
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